Advancing
a cell-based platform portfolio

OUR PIPELINE

Genenta - Our Pipeline
Genenta Our Pipeline  mobile

Gliobastoma Multiforme (TEM-GBM_001)

Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers. Biologically delivered via engineered tumor infiltrating monocytes (Tie2 expressing monocytes – TEMs), Temferon generates immune responses to any TEMs positive tumors.

As such the biological readouts and safety of Temferon in Glioblastoma patients should support the potential development of Temferon across a broad range of solid tumors that recruit TEMs.

Underlying Temferon is a platform technology that controls the expression of the therapeutic payload within the tumor microenvironment and can be applied to multiple different payloads. As a cell therapy, the impact is enduring, creating potentially life-long tumor surveillance.

Pin It on Pinterest